High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J., & Keller, G. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.008 · Cited by 1,159 · cited 1×
“9, eaaf2584 (2017) 15 February 2017 cardiomyocyte survival (25, 26).”
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., Hashimoto, H., Suzuki, T., Yamashita, H., Satoh, Y., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.09.013 · Cited by 1,037
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801 · cited 2×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundBurridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Self-citationLan, F., Lee, A. S., Liang, P., Sanchez-Freire, V., Nguyen, P. K., Wang, L., Han, L., Yen, M., Wang, Y., Sun, N., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.10.010 · Cited by 667
Self-citationCardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Liang, P., Lan, F., Lee, A. S., Gong, T., Sanchez-Freire, V., Wang, Y., Diecke, S., Sallam, K., Knowles, J. W., Wang, P. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001883 · Cited by 537 · cited 1×
“In vitro drug cardiotoxicity assessments also use nonhuman cells transfected with the human ether-à-go-go–related gene (hERG), which encodes a cardiac potassium channel, to evaluate drug-induced alterations in cardiac electrophysiology (5).”
BackgroundSelf-citationJonassen, A. K., Sack, M. N., Mjøs, O. D., & Yellon, D. M. (2001) · Circulation Research · doi:10.1161/hh2401.101385 · Cited by 523 · cited 2×
“This TKI-induced compensatory effect is fortuitous because insulin and IGF1 are cardioprotective during adverse cardiac events (17, 18).”
BackgroundTyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443 · cited 2×
“The high hiPSC-EC toxicity we observed with VEGFR2/ PDGFR-inhibiting TKIs such as ponatinib is consistent with the vascular toxicity observed clinically with these TKIs (1).”
BackgroundSelf-citationBuerke, M., Murohara, T., Skurk, C., Nuss, C., Tomaselli, K., & Lefer, A. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.8031 · Cited by 395 · cited 2×
“This TKI-induced compensatory effect is fortuitous because insulin and IGF1 are cardioprotective during adverse cardiac events (17, 18).”
BackgroundCardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Giordano, F. J., Gerber, H.-P., Williams, S.-P., VanBruggen, N., Bunting, S., Ruiz-Lozano, P., Gu, Y., Nath, A. K., Huang, Y., Hickey, R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091415198 · Cited by 370 · cited 1×
“9, eaaf2584 (2017) 15 February 2017 cardiomyocyte survival (25, 26).”
Favier, B., Alam, A., Barron, P., Bonnin, J., Laboudie, P., Fons, P., Mandron, M., Herault, J.-P., Neufeld, G., Savi, P., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4447 · Cited by 292 · cited 1×
“The VEGFR2/PDGFRinhibiting TKIs sorafenib, regorafenib, and ponatinib induced a twofold increase in the expression of neuropilin 2, a noncanonical VEGFR (29).”
BackgroundNatale, R. B., Thongprasert, S., Greco, F. A., Thomas, M., Tsai, C.-M., Sunpaweravong, P., Ferry, D., Mulatero, C., Whorf, R., Thompson, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5981 · Cited by 290
Mitcheson, J. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00128-x · Cited by 251 · cited 1×
“Primary human cardiomyocytes, which are ideal for assessing drug cardiotoxicities, are difficult to procure and maintain (6).”
BackgroundKim, G., McKee, A. E., Ning, Y.-M., Hazarika, M., Theoret, M., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 212
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben-Yehuda, O., & Moslehi, J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 201 · cited 2×
“Clinically, these TKIs cause cardiovascular toxicities including hypertension, heart failure, and QT prolongation (15).”
BackgroundSelf-citationMcDevitt, T. C., Laflamme, M. A., & Murry, C. E. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.007 · Cited by 183 · cited 2×
“effects of insulin/IGF1-induced proliferation, we used day 30 postdifferentiation hiPSC-CMs, which exhibit lower mitotic activity than do younger cells (28).”
BackgroundMethodWu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., Lan, F., Churko, J. M., Sallam, K. I., Matsa, E., Sharma, A., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.04.020 · Cited by 177
Self-citationKodo, K., Ong, S.-G., Jahanbani, F., Termglinchan, V., Hirono, K., InanlooRahatloo, K., Ebert, A. D., Shukla, P., Abilez, O. J., Churko, J. M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3411 · Cited by 171
Self-citationKantarjian, H. M., Cortes, J. E., Kim, D.-W., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E., Kelly, V., et al. (2014) · Blood · doi:10.1182/blood-2013-07-513937 · Cited by 151
Sharma, A., Marceau, C., Hamaguchi, R., Burridge, P. W., Rajarajan, K., Churko, J. M., Wu, H., Sallam, K. I., Matsa, E., Sturzu, A. C., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303810 · Cited by 148
Self-citationClinical cardiac safety profile of nilotinib
Kim, T. D., le Coutre, P., Schwarz, M., Grille, P., Levitin, M., Fateh‐Moghadam, S., Giles, F. J., Dörken, B., Haverkamp, W., & Köhncke, C. (2012) · Haematologica · doi:10.3324/haematol.2011.058776 · Cited by 118
LU, H. R., MARIËN, R., SAELS, A., & DE CLERCK, F. (2001) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2001.00093.x · Cited by 105 · cited 1×
“Preclinical platforms for evaluating drug cardiotoxicity use animal models, which inaccurately predict human cardiac pathophysiology because of interspecies differences in cardiac structure, electrophysiology, and genetics (4).”
BackgroundZang, J., Wu, S., Tang, L., Xu, X., Bai, J., Ding, C., Chang, Y., Yue, L., Kang, E., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030353 · Cited by 99
Self-citationChurko, J. M., Burridge, P. W., & Wu, J. C. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-511-8_7 · Cited by 94 · cited 1×
“Reprogramming of either skin fibroblasts or peripheral blood mononuclear cells to hiPSCs was conducted according to previously published protocols (8, 30).”
MethodSelf-citationCheng, H., Kari, G., Dicker, A. P., Rodeck, U., Koch, W. J., & Force, T. L. (2011) · Circulation Research · doi:10.1161/circresaha.111.255695 · Cited by 90
Talbert, D. R., Doherty, K. R., Trusk, P. B., Moran, D. M., Shell, S. A., & Bacus, S. S. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu215 · Cited by 84
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
Hill, A., Gotham, D., Fortunak, J., Meldrum, J., Erbacher, I., Martin, M., Shoman, H., Levi, J., Powderly, W. G., & Bower, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009586 · Cited by 68 · cited 1×
“DISCUSSION TKIs are a major class of cancer therapeutics, with revenues from these drugs annually reaching billions of dollars (19).”
BackgroundBronte, E., Bronte, G., Novo, G., Bronte, F., Bavetta, M. G., Re, G. L., Brancatelli, G., Bazan, V., Natoli, C., Novo, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5853 · Cited by 64
The Accelerated Approval of Oncologic Drugs
Prasad, V. K., & Mailankody, S. (2014) · JAMA · doi:10.1001/jama.2013.284531 · Cited by 60
Banerjee, I., Carrion, K., Serrano, R., Dyo, J., Sasik, R., Lund, S., Willems, E., Aceves, S., Meili, R., Mercola, M., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.003 · Cited by 59
Self-citationEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
Gunnarsson, Ö., Pfanzelter, N., Cohen, R. B., & O’Keefe, S. J. (2015) · Cancer Management and Research · doi:10.2147/cmar.s74202 · Cited by 56
Lee, B. S., Oh, J., Kang, S. K., Park, S., Lee, S., Choi, D., Chung, J. H., Chung, Y. W., & Kang, S.-M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135438 · Cited by 51
Crizotinib-Induced Cardiotoxicity: The Importance of a Proactive Monitoring and Management
Tartarone, A., Gallucci, G., Lazzari, C., Lerose, R., Lombardi, L., & Aieta, M. (2015) · Future Oncology · doi:10.2217/fon.15.47 · Cited by 50
QT Prolongation and Oncology Drug Development
Fradley, M. G., & Moslehi, J. J. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.03.013 · Cited by 48 · cited 1×
“Confirmation of toxicity for the known QT interval– prolonging TKIs nilotinib and vandetanib in hiPSC-CMs QT interval prolongation remains a major concern during drug development (16).”
BackgroundSelf-citation
Cited by
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Czerniecki, S. M., Cruz, N. M., Harder, J. L., Menon, R., Annis, J., Otto, E. A., Gulieva, R. E., Islas, L. V., Kim, Y. K., Tran, L. M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.04.022 · Cited by 465
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
“424 Indeed, adding exogenous insulin or IGF1 improves cardiomyocyte viability in the presence of tyrosine kinase inhibitors.”
BackgroundMetabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes
Feyen, D. A. M., McKeithan, W. L., Bruyneel, A. A. N., Spiering, S., Hörmann, L., Ulmer, B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107925 · Cited by 400
“The contractility image analysis and physiological parameter calculation were conducted as previously described (Sharma et al., 2017).”
Self-citationHuman iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection
Sharma, A., Garcia, G., Wang, Y., Plummer, J. T., Morizono, K., Arumugaswami, V., & Svendsen, C. N. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100052 · Cited by 318
“HiPSC-CMs can recapitulate cellular phenotypes for cardiovascular diseases including various forms of cardiomyopathy(19,20) and drug-induced cardiotoxicity.(21,22) Notably, hiPSC-CMs have also shown promise as an in vitro model for studying the mechanisms of direct CM viral infection in the context of viral myocarditi…”
BackgroundSelf-citation
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.